Melanoma-associated antigen genes - An update

Cancer Letters

Volumn 302, Issue 2, 2011, Pages 85-90

  Sang, Meixiang ^a   Wang, Lifang ^a   Ding, Chunyan ^a   Zhou, Xinliang ^a   Wang, Bin ^a   Wang, Ling ^a   Lian, Yishui ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Epigenetic activation; Immunotherapy; MAGE

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CASPASE 12; DOXORUBICIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 11; MELANOMA ANTIGEN A; MELANOMA ANTIGEN A3; MELANOMA ANTIGEN A4; MELANOMA ANTIGEN A9; MESSENGER RNA; P248V9 PEPTIDE; PACLITAXEL; PEPTIDE VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTIGEN EXPRESSION; APOPTOSIS; BLADDER TUMOR; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CARCINOMA IN SITU; CELL CYCLE PROGRESSION; EPIGENETICS; GENE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MELANOMA ASSOCIATED ANTIGEN A1 GENE; MELANOMA ASSOCIATED ANTIGEN I GENE; MELANOMA ASSOCIATED ANTIGEN II GENE; MELANOMA CELL; MULTIGENE FAMILY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY;

EID: 79951576721     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.021     Document Type: Review

References (59)

1. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
3. Rogner U.C., Wilke K., Steck E., Korn B., Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 1995, 29:725-731.
4. Dabovic B., Zanaria E., Bardoni B., Lisa A., Bordignon C., Russo V., et al. A family of rapidly evolving genes from the sex reversal critical region in Xp21. Mamm. Genome 1995, 6:571-580.
5. Lurquin C., De Smet C., Brasseur F., Muscatelli F., Martelange V., De Plaen E., et al. Two members of the human MAGEB gene family located in Xp.21.3 are expressed in tumors of various histological origins. Genomics 1997, 46:397-408.
6. Muscatelli F., Walker A.P., De Plaen E., Stafford A.N., Monaca A.P. Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl. Acad. Sci. USA 1995, 92:4987-4991.
7. Lucas S., De Smet C., Arden K.C., Viars C.S., Lethé B., Lurquin C., et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 1998, 58:743-752.
8. Lucas S., De Plaen E., Boon T. MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 2000, 87:55-60.
9. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5:615-625.
10. Jungbluth A.A., Busam K.J., Kolb D., Iversen K., Coplan K., Chen Y.T., et al. Expression of MAGE-antigens in normal tissues and cancer. Int. J. Cancer 2000, 85:460-465.
11. Osterlund C., Töhönen V., Forslund K.O., Nordqvist K. Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. Cancer Res. 2000, 60:1054-1061.
12. Castelli C., Rivoltini L., Andreola G., Carrabba M., Renkvist N., Parmiani G. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol. 2000, 182:323-331.
13. Atanackovic D., Altorki N.K., Stockert E., Wiliamson B., Jungbluth A.A., Ritter E., et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 2004, 172:3289-3296.
14. Sugita M., Geraci M., Gao B., Powell R.L., Hirsch F.R., Johnson G., et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002, 62:3971-3979.
15. Kufer P., Zippelius A., Lutterbüse R., Mecklenburg I., Enzmann T., Montag A., et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res. 2002, 62:251-261.
16. Jang S.J., Soria J.C., Wang L., Hassan K.A., Morice R.C., Walsh G.L., et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res. 2001, 61:7959-7963.
17. Andrade V.C., Vettore A.L., Felix R.S., Almeida M.S., Carvalho F., Oliveira J.S., et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008, 8:2.
18. Picard V., Bergeron A., Larue H., Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int. J. Cancer 2007, 120:2170-2177.
19. Otte M., Zafrakas M., Riethdorf L., Pichlmeier U., Loning T., Jänicke F., et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 2001, 61:6682-6687.
20. Busam K.J., Iversen K., Berwick M., Spagnoli G.C., Old L.J., Jungbluth A.A., et al. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod. Pathol. 2000, 13:459-465.
21. Rimoldi D., Salvi S., Schultz-Thater E., Spagnoli G.C., Cerottini J.C. Anti-MAGE-3antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int. J. Cancer 2000, 86:749-751.
22. Bergeron A., Picard V., LaRue H., Harel F., Hovington H., Lacombe L., et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int. J. Cancer 2009, 125:1365-1371.
23. Bandić D., Juretić A., Sarcević B., Separović V., Kujundzić-Tiljak M., Hudolin T., et al. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat. Med. J. 2006, 47:32-41.
24. Brasseur F., Rimoldi D., Liénard D., Lethé B., Carrel S., Arienti F., et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 1995, 63:375-380.
25. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 1994, 54:1766-1771.
26. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 1996, 93:7149-7153.
27. De Smet C., Courtois S.J., Faraoni I., Lurquin C., Szikora J.P., De Backer O., et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995, 42:282-290.
28. De Smet C., Lurquin C., Lethé B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999, 19:7327-7335.
29. Suyama T., Ohashi H., Nagai H., Hatano S., Asano H., Murate T., et al. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. Leukemia Res. 2002, 26:113-1118.
30. Karpf A.R., Lasek A.W., Ririe T.O., Hanks A.N., Grossman D., Jones D.A., et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol. Pharmacol. 2004, 65:18-27.
31. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 2006, 4:339-349.
32. Goodyear O., Agathanggelou A., Novitzky-Basso I., Siddique S., McSkeane T., Ryan G., et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 8(June).
33. Taniura H., Taniguchi N., Hara M., Yoshikawa K. Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J. Biol. Chem. 1998, 273:720-728.
34. Taniura H., Matsumoto K., Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J. Biol. Chem. 1999, 274:16242-16248.
35. Salehi A.H., Roux P.P., Kubu C.J., Zeindler C., Bhakar A., Tannis L.L., et al. NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron 2000, 27:279-288.
36. Jordan B.W., Dinev D., LeMellay V., Troppmair J., Gotz R., Wixler L., et al. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J. Biol. Chem. 2001, 276:39985-39989.
37. Masuda Y., Sasaki A., Shibuya H., Ueno N., Ikeda K., Watanabe K. Dlxin-1, a novel protein that binds Dlx5 and regulates its transcriptional function. J. Biol. Chem. 2001, 276:5331-5338.
38. Saburi S., Nadano D., Akama T.O., Hirama K., Yamanouchi K., Naito K., et al. The trophinin gene encodes a novel group of MAGE proteins, magphinins, and regulates cell proliferation during gametogenesis in the mouse. J. Biol. Chem. 2001, 276:49378-49389.
39. Morishima N., Nakanishi K., Takenouchi H., Shibata T., Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J. Biol. Chem. 2002, 277:34287-34294.
40. Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B.A., et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403:98-103.
41. Lamkanfi M., Kalai M., Vandenabeele P. Caspase-12: an overview. Cell. Death. Differ. 2004, 11:365-368.
42. Bai S., He B., Wilson E.M. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol. Cell. Biol. 2005, 25:1238-1257.
43. Bai S., Wilson E.M. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol. Cell. Biol. 2008, 28:1947-1963.
44. Aprelikova O., Pandolfi S., Tackett S., Ferreira M., Salnikow K., Ward Y., et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res. 2009, 69:616-624.
45. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 2006, 103:11160-11165.
46. Duan Z., Duan Y., Lamendola D.E., Yusuf R.Z., Naeem R., Penson R.T., et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 2003, 9:2778-2785.
47. Yang B., O'Herrin S., Wu J., Reagan-Shaw S., Ma Y., Nihal M., et al. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J. Invest. Dermatol. 2007, 27:267-275.
48. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007, 67:9954-9962.
49. Sakurai T., Itoh K., Higashitsuji H., Nagao T., Nonoguchi K., Chiba T., et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J. Biol. Chem. 2004, 279:15505-15514.
50. Peikert T., Specks U., Farver C., Erzurum S.C., Comtair S.A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res. 2006, 66:4693-4700.
51. Nagao T., Higashitsuji H., Nonoguchi K., Sakurai T., Dawson S., Mayer R.J., et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. 2003, 278:10668-10674.
52. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000, 6:96-99.
53. Yoshida N., Abe H., Ohkuri T., Wakita D., Sato M., Noguchi D., et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int. J. Oncol. 2006, 28:1089-1098.
54. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S., et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 2002, 169:575-580.
55. Jäger E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jäger D., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 1997, 71:142-147.
56. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 1996, 98:1633-1641.
57. Zeh H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 1999, 162:989-994.
58. Liu K., Schoonmaker M.M., Levine B.L., June C.H., Hodes R.J., Weng N.P. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl. Acad. Sci. USA 1999, 96:5147-5152.
59. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 2009, 10:371-374.